Trial Profile
A double-blind, randomized, placebo-controlled, single dose escalation study to investigate the safety, tolerability and pharmacokinetics of GSK1349572 in healthy subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Jul 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 01 Jan 2010 Results published in the Antimicrobial Agents and Chemotherapy.
- 21 Apr 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
- 27 Mar 2008 New trial record.